Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 3—March 2016
Online Report

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis

Jennifer FurinComments to Author , Grania Brigden, Erica Lessem, Michael Rich, Laura Vaughan, and Sharonann Lynch
Author affiliations: Harvard Medical School, Boston, Massachusettes, USA (J. Furin); Médecins Sans Frontières Access Campaign, Geneva, Switzerland (G. Brigden, S. Lynch); Treatment Action Group, New York, NY, USA (E. Lessem); Brigham and Women’s Hospital, Boston (M. Rich); Partners In Health, Boston (M. Rich, L. Vaughan)

Main Article

Table 5

Progress in achieving targets set in global call to action for the programmatic use of bedaquiline and delamanid to treat multidrug-resistant tuberculosis

Target Status
500 Patients on BDQ by July 2015 1,258 patients by October 1, 2015
500 Patients on DLM by Jan 2016 >100 patients by October 1, 2015
TA given to 25 countries by 2016
Ongoing, already provided in 21 countries
BDQ and DLM routinely used by 20 countries by end of 2016 BDQ: 9 countries plus European Union by October 1, 2015; additional 20 by the mid-2016

DLM: 2 countries plus European Union by October 1, 2015; plans for other countries expected to be discussed in December 2015
BDQ and DLM dossiers submitted for registration in 25 countries by beginning of 2016 BDQ: 26 countries by October 1, 2015
DLM: 3 countries by October 1 2015

*BDQ, bedaquiline; DLM, delamanid.

Main Article

Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.